Oral Wegovy Lands in Germany With Novo 58% Under GF Value
Novo Nordisk has made Germany the first EU market for the Wegovy pill, arriving with the shares near 58% below GF Value and Eli Lilly widening its own oral push.
Novo Nordisk launched the oral formulation of Wegovy in Germany, the first EU market to receive the pill, while its shares closed at 45.12 on Sept. 1, 2026 — nearly 58% below GuruFocus's GF Value estimate.
Novo Nordisk (NVO) has begun selling the oral version of Wegovy in Germany, making it the first market in the European Union to receive the pill formulation of the company's flagship obesity drug. The launch arrives with the shares carrying an unusually wide valuation gap: NVO closed at 45.12 on Sept. 1, 2026, down 0.46% on the day, and trades nearly 58% below GuruFocus's GF Value estimate, according to GuruFocus.
GF Value is GuruFocus's own intrinsic-value estimate, built from a company's historical trading multiples, past growth and analyst forward estimates. It is a model output, not a price target from a broker. A stock sitting well below it can mean one of two things: the market has repriced the business for a slower future than history implies, or the model has not caught up with the market's fear. Which of those applies to Novo is the question the German launch starts to answer.
Why Germany goes first
Germany is the natural beachhead for an oral obesity drug in Europe. It is the bloc's largest pharmaceutical market by value, it has a well-established statutory reimbursement machinery, and it has been the entry point for a long list of prior launches. Making it the first EU market for oral Wegovy tells you Novo wants a real-world read on pricing, prescribing behaviour and volume before it scales the rollout across the rest of the continent.
The strategic logic of a pill is straightforward. Injectable GLP-1 medicines — the class that includes Wegovy — require refrigeration, pens, needles and a patient willing to inject weekly. A tablet removes each of those frictions. It widens the addressable pool to people who will not inject, it simplifies pharmacy logistics, and it changes the manufacturing constraint from fill-finish injectable capacity to tablet production. For a company that spent much of the GLP-1 boom supply-constrained, that last point is not a small one.
The competitive clock is running
The counterweight is Eli Lilly (LLY), which continues to expand its own presence in the obesity market. LLY closed at 1160.00 on Sept. 1, 2026, up 0.28% on the day, after ranging between 1156.85 and 1188.33 during the session. The two closes point in opposite directions on the day, and that divergence is a compressed version of the wider narrative: investors have been rewarding Lilly's momentum while marking Novo's first-mover position down.
Being first with a pill in an EU market is worth something, but the value decays. Early entry buys formulary placement, prescriber habit and brand recognition among patients who ask for a drug by name. It does not buy exclusivity against a rival with a competitive oral asset and a large commercial organisation. The real question for Novo shareholders is how much durable share the German launch converts before Lilly's expansion reaches the same shelves.
Discount as risk, or discount as opportunity
A near-58% gap to GF Value is large enough that it cannot be waved away as noise. Two readings are available and neither is provable from the price alone.
- The earnings-risk reading. The market has concluded that obesity-drug economics will not hold. Pricing pressure from payers, a second and third credible entrant, and the arrival of oral options that are cheaper to make all point toward lower revenue per patient. If that is right, GF Value is anchored to a margin structure that no longer exists, and the discount is not a discount at all — it is an accurate repricing.
- The mispricing reading. Volume growth in obesity treatment is still early, oral dosing materially expands the eligible patient base, and a franchise that dominates a category can trade below its own history for reasons of sentiment rather than fundamentals. On this view, the German launch is the first datapoint in a series that closes the gap.
The distinction matters because the two paths look identical for a while. Both begin with a stock well below model value. They diverge only when volumes and net pricing are reported.
What the tape said on the day
The session itself was soft across the board. The S&P 500 tracker SPY closed at $761.78, down 0.69%; the Nasdaq 100 tracker QQQ finished at $707.64, down 1.27%; and the Dow tracker DIA ended at $527.75, down 0.72%. Against that backdrop, Novo's 0.46% decline was a shade better than the broad market and Lilly's small gain stood out. Neither move is a verdict on the launch — one session rarely is — but it does show the German news did not, by itself, force a re-rating.
46% decline was a shade better than the broad market and Lilly's small gain stood out.
NVO traded between 45.06 and 46.16 on the day, closing nearer the low. Lilly's range was wider in absolute terms, from 1156.85 to 1188.33, with the close at the bottom end of it.
What to watch from here
Three things will determine whether the German launch is a turning point or a footnote.
- Reimbursement outcomes. Germany's pricing negotiations for new medicines are among the most consequential in Europe. Where oral Wegovy lands on net price will set an anchor for every subsequent EU market.
- The rollout schedule. Germany first implies others follow. The pace and the sequence will indicate how confident Novo is in its tablet supply and how aggressive it intends to be before competing oral products arrive.
- Whether the pill grows the market or cannibalises the pen. If oral Wegovy pulls in patients who were never going to inject, it is additive. If it simply converts existing injectable users at a lower price point, revenue per patient falls and the earnings-risk reading of the valuation gap gains support.
For now, the position is unambiguous on the facts and ambiguous on the interpretation: Novo has the first oral GLP-1 in an EU market, and it has a share price the market values at well under half of what its own trading history would imply. Those two statements sit uncomfortably together, which is precisely why the German numbers, when they arrive, will be read closely.
Key facts
- NVO last close: 45.12, -0.46% (as of Sept. 1, 2026, 20:00 GMT)
- LLY last close: 1160.00, +0.28% (as of Sept. 1, 2026, 20:00 GMT)
- Valuation gap: Novo Nordisk trades nearly 58% below GF Value
- Launch market: Germany — first EU market for oral Wegovy
Frequently asked questions
What is oral Wegovy and why does it matter?
Oral Wegovy is a tablet formulation of Novo Nordisk's obesity treatment, which has been delivered by weekly injection. A pill removes the need for needles, pens and refrigerated handling, which widens the pool of patients willing to start treatment and changes the manufacturing bottleneck from injectable fill-finish capacity to tablet production.
Why did Novo Nordisk choose Germany first in the EU?
Germany is the European Union's largest pharmaceutical market by value and has an established statutory reimbursement system, making it a common first stop for major launches. Starting there gives Novo Nordisk a real-world read on pricing, prescriber behaviour and demand volumes before extending the oral Wegovy rollout to other EU countries.
What does 'trading 58% below GF Value' actually mean?
GF Value is GuruFocus's proprietary intrinsic-value estimate, calculated from a company's historical trading multiples, past growth rates and forward analyst estimates. A stock nearly 58% below it means the market price sits at well under half that modelled value. It signals either a genuine repricing of future earnings or a potential mispricing.
How did Novo Nordisk and Eli Lilly shares close on Sept. 1, 2026?
NVO closed at 45.12, down 0.46% from a prior close of 45.33, with a day range of 45.06 to 46.16. LLY closed at 1160.00, up 0.28% from 1156.73, ranging between 1156.85 and 1188.33 during the session. The market was closed at the time of these quotes.
How does Eli Lilly factor into the oral obesity drug race?
Eli Lilly is expanding its position in the obesity treatment market, which limits how long Novo Nordisk's first-mover advantage on an EU oral launch can hold. Early entry secures formulary placement and prescriber habit, but it does not confer exclusivity against a rival with a competitive product and a large commercial organisation.
What should investors watch next after the German launch?
Three signals matter: the outcome of Germany's reimbursement negotiations, which will anchor net pricing across Europe; the pace and sequence of the rollout into other EU markets; and whether the pill attracts new patients or simply converts existing injectable users, which would lower revenue per patient.
Sources
Photo: Christina & Peter · Pexels Licence — source
